Genmab (Otc) (GMAB) has released an update.
Genmab A/S reported robust first quarter sales for 2024, announcing net sales of DARZALEX (daratumumab) amounting to USD 2,692 million globally. This revenue includes sales from both the intravenous and subcutaneous forms of DARZALEX, with the company earning royalties on these worldwide sales through its licensing agreement with Janssen Biotech, Inc. The biotech firm continues to innovate in the field of antibody therapeutics, aiming to transform patient lives with their advanced medicines.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
